PYC Therapeutics Limited (ASX:PYC)

Australia flag Australia · Delayed Price · Currency is AUD
1.210
-0.030 (-2.42%)
Aug 1, 2025, 4:10 PM AEST
-2.42%
Market Cap705.75M
Revenue (ttm)24.99M
Net Income (ttm)-48.20M
Shares Out583.26M
EPS (ttm)-0.11
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume506,296
Average Volume490,017
Open1.240
Previous Close1.240
Day's Range1.205 - 1.262
52-Week Range0.891 - 2.080
Beta0.56
RSI36.16
Earnings DateAug 29, 2025

About Accolade

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program which is Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for the treatment of blinding eye disease; PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder; and PYC-003, which is indicated to treat autosomal dominant polycystic kidney disease. PYC Therapeuti... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 5
Stock Exchange Australian Securities Exchange
Ticker Symbol PYC
Full Company Profile

Financial Performance

In 2024, PYC Therapeutics's revenue was 22.06 million, an increase of 39.56% compared to the previous year's 15.81 million. Losses were -37.73 million, 65.5% more than in 2023.

Financial Statements

News

There is no news available yet.